Release Date: 2024-04-04

Dyslipidemia Screening

Turgay Aras (Author)

Release Date: 2024-04-04

Dyslipidemia is lipoprotein metabolism disorders characterized by high total cholesterol (TC), LDL-C, non-HDL-C, triglyceride (TG) and low HDL-C.Although lipid and lipoprotein levels vary according to age and gender, acceptable, borderline high and high values ​​have been determined for children.Dyslipidemia can occur for various reasons, such as dietary saturated and trans fats, consumption of refined carbohydrates [...]

Media Type
  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inNewborn and Childhood Screening Programmes
First Page147
Last Page155
DOIhttps://doi.org/10.69860/nobel.9786053358961.13
ISBN978-605-335-896-1 (PDF)
LanguageENG
Page Count9
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing
Dyslipidemia is lipoprotein metabolism disorders characterized by high total cholesterol (TC), LDL-C, non-HDL-C, triglyceride (TG) and low HDL-C.Although lipid and lipoprotein levels vary according to age and gender, acceptable, borderline high and high values ​​have been determined for children.Dyslipidemia can occur for various reasons, such as dietary saturated and trans fats, consumption of refined carbohydrates and sugar, alcohol, medications, endocrine/metabolic/renal problems, infections and genetic factors.The frequency and duration of dyslipidemia screening are planned according to age and risk factors for early ASCVD and the presence of a history of familial hypercholesterolemia or early ASCVD.Screening includes TC, HDL-C, TG measured in fasting or postprandial states, and calculated LDL-C and non-HDL-C. If there are abnormalities, fasting lipid profiles are used for confirmation. Non-HDL-C is calculated by subtracting HDL-C from total cholesterol and is important for dyslipidemia screening.Screening Results: Acceptable levels; No further evaluation is required, regular screenings continue. Borderline high results; Diet and healthy lifestyle are recommended, no medical treatment is required. Scans may be repeated within a year. Abnormally high results; It should be confirmed with a fasting lipid profile, and dietary and lifestyle changes should be implemented. Medical treatment may be required, secondary causes should be investigated. In case of very high LDL-C (≥250 mg/dL), referral should be made to relevant specialists.Screening only those with certain risk factors such as familial hypercholestrolonemia, obesity, and diabetes causes many children with dyslipidemia to go undetected and increases the risk of atherosclerotic ASCVD and the severity of the disease at older ages. Therefore, screening for dyslipidemia in childhood is very important in terms of early diagnosis and control of dyslipidemia.

Turgay Aras (Author)
Assistant Professor, Ataturk University
https://orcid.org/0009-0001-8500-9199
3Turgay Aras is a scientist who has been a physician for more than 23 years and has been working as a pediatrician for the last eight years. He graduated from Atatürk University Faculty of Medicine between 1993 and 2000. He worked in various positions at the Ministry of Health between 2000 and 2013. Between 2013 and 2017, he completed his specialization training in Atatürk University Faculty of Medicine, Department of Child Health and Diseases. He currently works at Atatürk University Faculty of Medicine, Department of Child Health and Diseases.

  • Daniels, S. R., Greer, F. R., & Nutrition, C. o. (2008). Lipid screening and cardiovascular health in childhood. Pediatrics, 122(1), 198-208.

  • ypercholesterolemia, obesity, diabetes, etc. leads to a significant number of children with dyslipidemia going unrecognized. Therefore, screening for dyslipidemia in childhood will contribute to controlling dyslipidemia with early diagnosis and reducing the risk and/or severity of ASCVD in later life (Heal

  • Health, E. P. o. I. G. f. C., Children, R. R. i., & Adolescents. (2011). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics, 128(Supplement_5), S213-S256.

  • Neal, W. A., & John, C. C. (2016). Disoders of lipoprotein metabolism and transport. Nelson textbook of pediatrics, 470-471.

  • Sarah D de Ferranti, M., MPHJane W Newburger, MD, MPH. (2024). Dyslipidemia in children and adolescents: Defi nition, screening, and diagnosis. https://www.uptodate.com/contents/dyslipidemia-in-children-and-adolescents-defi nition-screening-and-diagnosis?search=dislipidemiler&source=- search_result&selectedTitle=3%7E150&usage_type=default&display_rank=3#H235228239

  • Tumer, L., & Kasapkara, Ç. S. (2013). Çocuklarda Hiperlipidemi Taraması. Turkiye Klinikleri Journal of Pediatrics, 22(4), 171-177.

Share This Chapter!